A large body of evidence suggested that the activation of AXL is associated with TKI-resistance in several cancers, such as gastrointestinal stromal tumors, ovarian cancer, triple-negative breast cancer and chronic myeloid leukemia [24–26]. Here, AXL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.